Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating eribulin mesylate with pembrolizumab in metastatic triple-negative breast cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasm
• Triple-negative Breast Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Eisai Inc. | Conditions: Breast Neoplasm | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-08-14